Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Net Income (2016 - 2025)

CorMedix's Net Income history spans 14 years, with the latest figure at -$11.8 million for Q4 2025.

  • For Q4 2025, Net Income fell 194.07% year-over-year to -$11.8 million; the TTM value through Dec 2025 reached $137.8 million, up 829.96%, while the annual FY2025 figure was $137.3 million, 876.74% up from the prior year.
  • Net Income for Q4 2025 was -$11.8 million at CorMedix, down from $108.6 million in the prior quarter.
  • Across five years, Net Income topped out at $108.6 million in Q3 2025 and bottomed at -$14.5 million in Q1 2024.
  • The 5-year median for Net Income is -$7.6 million (2022), against an average of $1.4 million.
  • The largest YoY upside for Net Income was 4002.28% in 2025 against a maximum downside of 194.07% in 2025.
  • A 5-year view of Net Income shows it stood at -$9.7 million in 2021, then increased by 15.03% to -$8.2 million in 2022, then dropped by 18.11% to -$9.7 million in 2023, then skyrocketed by 229.04% to $12.5 million in 2024, then crashed by 194.07% to -$11.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Net Income are -$11.8 million (Q4 2025), $108.6 million (Q3 2025), and $20.3 million (Q2 2025).